AbbVie to acquire Landos Biopharma
26 Mar 2024
ImmunotherapyPhase 2AcquisitionDrug ApprovalAccelerated Approval
AbbVie has announced an agreement to acquire Landos Biopharma, a company specializing in the development of oral therapeutics for autoimmune diseases.
AbbVie will purchase Virginia-based Landos for $20.42 per share in cash, amounting to approximately $137.5 million, with an additional up to $11.14 per share contingent upon achieving a clinical milestone, totaling up to approximately $212.5 million. The transaction is expected to close in the second quarter of 2024, subject to Landos' shareholders' approval and other customary closing conditions.
The deal centers on Landos' lead compound, NX-13, an oral NLRX1 agonist currently in phase 2 clinical trials for the treatment of ulcerative colitis and Crohn's disease. NX-13 aims to reduce inflammation and facilitate tissue repair in the gastrointestinal tract.
The deal is the latest in a series of acquisitions for AbbVie. Back in December, the drugmaker announced its intent to acquire Cerevel Therapeutics in a potential $8.7 billion bid to bolster AbbVie's presence in the neuroscience sector. Among the standout Cerevel assets is emraclidine, a positive allosteric modulator currently undergoing phase 2 trials for schizophrenia.
Last month, AbbVie finalized its acquisition of ImmunoGen, incorporating the Massachusetts-based company's leading cancer treatment, Elahere, into its offerings. The purchase of ImmunoGen was initially revealed in November. AbbVie bought all outstanding shares of ImmunoGen at $31.26 each in cash, putting ImmunoGen's value at around $10.1 billion.
Elahere, which received accelerated approval in November 2022 for treating FRα-positive ovarian, fallopian tube, or primary peritoneal cancer, marks the first FDA-approved antibody-drug conjugate for this condition. The acquisition also granted AbbVie entry to ImmunoGen's advanced pipeline of next-generation ADCs, which hold promise as treatments for a variety of solid tumors and blood cancers.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.